title: [Efficacy and safety of sitafloxacin for lower respiratory tract infections].
abstract: We investigated the efficacy and safety of sitafloxacin (STFX) in patients with mild to moderate community-acquired pneumonia or secondary infections of chronic respiratory tract diseases. The results showed that the efficacy rate was 96.5% (111/115) in patients analyzed for efficacy. The efficacy rate by STFX administration method was 93.9% (46/49) at 50mg b.i.d., 100% (37/37) at 100 mg q.d. and 96.6% (28/29) at 100mg b.i.d. In chest X-rays, the image improvement rate in 102 patients with shadows before treatment was 94.1% (96/102). The image improvement rate by STFX administration method was 90.5% (38/42) at 50 mg b.i.d., 97.1% (33/34) at 100mg q.d. and 96.2% (25/26) at 100mg b.i.d. Side effects occurred in five out of 115 patients (4.3%). Abnormalities in hepatic function test values appeared in two patients and abnormalities in renal function test values appeared in three patients. In four cases, the abnormalities were very mild and STFX administration was continued without any treatment. In the other patient, the abnormal value rapidly returned to normal after STFX administration was discontinued. These findings indicated that STFX can be used safety in routine practice by adjusting the administration within the approved dose based on patient characteristics. Good therapeutic effects can be expected in patients with respiratory tract infections.
authors.affiliation: Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mukae
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yatera
authors.forename: Shuya
authors.initials: S
authors.lastname: Nagata
authors.forename: Kei
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Chinatsu
authors.initials: C
authors.lastname: Nishida
authors.forename: Toshinori
authors.initials: T
authors.lastname: Kawanami
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishimoto
authors.forename: Chiharu
authors.initials: C
authors.lastname: Yoshii
authors.forename: Naomasa
authors.initials: N
authors.lastname: Inoue
authors.forename: Shingo
authors.initials: S
authors.lastname: Noguchi
authors.forename: Yukikazu
authors.initials: Y
authors.lastname: Awaya
authors.forename: Tatsunori
authors.initials: T
authors.lastname: Kawajiri
authors.forename: Tomotoshi
authors.initials: T
authors.lastname: Imanaga
authors.forename: Takashi
authors.initials: T
authors.lastname: Kido
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Choujin
authors.forename: Hideto
authors.initials: H
authors.lastname: Obata
authors.forename: Atsushi
authors.initials: A
authors.lastname: Matsushima
authors.forename: Yu
authors.initials: Y
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017714:Community-Acquired Infections / Q000188:drug therapy; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C076246:sitafloxacin